DAX+0,90 % EUR/USD+0,05 % Gold+0,26 % Öl (Brent)+0,51 %

UCB Full Year Report 2018 2018 Marks the Fifth Consecutive Year of Profitable Growth, Intensifying Investment in UCB's Strong Pipeline

Nachrichtenquelle: PR Newswire (engl.)
28.02.2019, 20:04  |  1855   |   |   

 - Revenue reached € 4.6 billion: +2%, +5% CER1; net sales increased to € 4.4 billion: +5%, +8% CER, driven by core products (+6%, +10% CER) 

- Underlying profitability (rEBITDA) increased to € 1 398 million: 2%, +5% CER

- R&D update: Evenity approved in Japan; Vimpat approved in China

- Financial outlook for 2019: Revenue expected in the range of € 4.6 - 4.7 billion, recurring EBITDA2 in the range of 27% - 29% of revenue, reflecting higher R&D investments 

BRUSSELS, Feb. 28, 2019 /PRNewswire/ -- "We are confident for the future growth of UCB based on strong delivery in 2018, marking the fifth year of profitable growth in a row and a new blockbuster for UCB, Vimpat," said Jean-Christophe Tellier, CEO UCB. "We are expecting Cimzia to reach € 1.7 billion net sales by 2024 and Vimpat should reach 1.4 billion by 2022. Our strong late stage pipeline currently offers six potential product launches in the next five years. Based on our solid foundation we will as planned accelerate our investments in future growth drivers."  

Core product net sales

Revenue for 2018 reached € 4.63 billion, +2% at actual and +5% at constant exchange rates (CER). Net sales went up by 5% (+8% CER) to € 4.41 billion, driven by the continued growth of UCB's five core products, with combined net sales of € 3.8 billion (+6%; +10% CER), representing 82% of UCB's revenue.

Underlying profitability (rEBITDA2) improved by 2% (+5% CER) to € 1 398 million - thanks to core product growth and despite higher R&D expense.

Profit of the Group, supported by a tax rate of 19.7%, increased to € 823 million - of which € 800 million (+6%; +10% CER) is attributable to the UCB shareholders.
The Board of directors of UCB proposes a dividend of €1.21 per share (gross), +2.5%.

UCB's financial results FY 2018:








€ million

FY 2018

FY 2017

Act

CER


Revenue

4 632

4 530

2%

5%


Net sales

4 412

4 182

5%

8%


rEBITDA2

1 398

1 375

2%

5%


Number of shares (m)

188

188




Core EPS3 (€)

4.78

4.82

-1%

3%


Dividend per share (€)

1.21

1.18

2.5%


Latest R&D update

Neurology –

In October, UCB announced positive results from a phase 2 study with a novel, subcutaneous FcRn (neonatal Fc receptor) monoclonal antibody, rozanolixizumab, in patients with myasthenia gravis (MG), achieving proof-of-concept. These results support the rozanolixizumab development with a confirmatory study in MG starting in Q2 2019.

In December, Vimpat (lacosamide) was approved in China as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in adult and adolescent patients 16 years of age and older with epilepsy.
In January 2019, Vimpat was approved in Japan for the treatment of partial onset seizures in children 4 years of age and older. In addition, two new formulations have been approved, IV (intravenous) and dry syrup. 

Seite 1 von 14


0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel
Aus der Redaktion